Lymphedema – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Lymphedema is a chronic ailment characterized by the accumulation of lymphatic fluid within the body, resulting in swelling and potential alterations in skin and tissue. This condition emerges due to the persistent buildup of protein-rich fluid in the interstitial spaces and fibro-adipose tissue, surpassing the lymphatic system's ability to transport the fluid effectively. Swelling, a hallmark of lymphedema, can manifest in various body parts, including the arms, legs, face, neck, genitals, chest wall, and oral cavity. The diagnosis of lymphedema brings about a range of psychological, physical, and social consequences. It is classified into two main types: primary lymphedema, which is genetic, and secondary lymphedema, which arises from external causes. Lymphedema's signs and symptoms encompass swelling in the extremities, like the arms, hands, legs, and feet. Additionally, it can lead to swelling in the breast, chest, shoulder, pelvis, groin, face, and intraoral tissues. Movement in joints becomes restricted due to swelling and tissue alterations, and there might be skin discoloration, pain, changed sensation, limb heaviness, and challenges with clothing fitting properly. Primary lymphedema is an inherent or congenital disorder brought about by lymphatic system malformation, often due to genetic mutations. This type can be categorized into three subtypes: congenital lymphedema, apparent from birth or within the initial two years of life; lymphedema praecox, which occurs around puberty or the start of the third decade; and lymphedema tarda, which commences after the age of 35. Secondary lymphedema, on the other hand, emerges due to damage, injury, or blockage of the lymphatic system. The severity of lymphedema is often described through a staging system:
1. Stage 0:
No observable swelling, but subtle sensations such as a heavy or full feeling
in the affected area or tight skin.
2. Stage 1 -
Swelling in the affected area, with increased size and stiffness. Elevation of
the limb tends to alleviate the swelling.
3. Stage 2 -
Greater swelling compared to stage 1, not improved by elevation. The affected
area becomes hard and larger.
4. Stage 3 -
Significantly more swelling than in stage 2. The extremity might become so
swollen that self-movement is impeded. Skin dryness and thickening can lead to
fluid leakage or blister formation.
Complications associated with
lymphedema encompass recurrent Cellulitis, Lymphangitis, Superficial bacterial
and fungal infections, Lymphangio-adenitis, and Deep vein thrombosis (DVT).
Post-surgery, complications like Partial wound separation, Seroma, Hematoma,
and Skin necrosis are common. Unfortunately, there is no definitive cure for
lymphedema. Treatment primarily revolves around diminishing swelling and
averting complications. Diligent therapeutic approaches and preventive measures
are crucial in mitigating symptoms, slowing or halting disease progression, and
preventing further complications. Patients with chronic lymphedema over a
decade face a 10% risk of developing lymphangiosarcoma. This aggressive tumor
often necessitates extremity amputation and carries a very poor prognosis, with
less than 10% five-year survival rate.
·
Primary lymphedema is a rarity, impacting just
one in every 100,000 individuals. In contrast, secondary lymphedema is the
predominant cause of the condition, afflicting around one in every 1,000
Americans.
Thelansis’s “Lymphedema Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Lymphedema treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Lymphedema across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Lymphedema Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment